Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000518358 | SCV000615129 | uncertain significance | not specified | 2016-12-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000765524 | SCV000896838 | uncertain significance | Primary erythromelalgia; Neuropathy, hereditary sensory and autonomic, type 2A; Paroxysmal extreme pain disorder; Severe myoclonic epilepsy in infancy; Channelopathy-associated congenital insensitivity to pain, autosomal recessive; Generalized epilepsy with febrile seizures plus, type 7 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001203277 | SCV001374433 | likely benign | Neuropathy, hereditary sensory and autonomic, type 2A; Generalized epilepsy with febrile seizures plus, type 7 | 2023-09-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004965527 | SCV005501669 | uncertain significance | Inborn genetic diseases | 2024-10-01 | criteria provided, single submitter | clinical testing | The c.3505A>G (p.N1169D) alteration is located in exon 19 (coding exon 18) of the SCN9A gene. This alteration results from a A to G substitution at nucleotide position 3505, causing the asparagine (N) at amino acid position 1169 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |